Background: The PARADIGM HF trial showed sacubitril/valsartan (SV) to be superior to
enalapril in patients with reduced ejection fraction (HFrEF). Since its publication, several …

Purpose The objective of this meta-analysis is to determine how sacubitril/valsartan (SV)
compares to equivalent and sub-equivalent angiotensin receptor blockers (ARB) or …

This review aims to assess the benefits and adverse effects of sacubitril/valsartan in heart
failure, with a focus on important patient outcomes. A systematic review was conducted of …

Current guidelines recommend angiotensin receptor blocker neprilysin inhibitors
(ARNI)(sacubitril/valsartan) as a replacement for angiotensin-converting-enzymeinhibitor …

Objective Heart failure with preserved ejection fraction (HFpEF) is a prevalent and clinically
significant condition characterized by limited treatment options. In this context, the objective …

We conducted a systematic review and meta-analysis to assess all-cause mortality and
heart failure (HF) hospitalization with sacubitril/valsartan (S/V) compared to standard HF …

Purpose of review Compared to enalapril, use of angiotensin-receptor blocker and
neprilysin inhibitor sacubitril/valsartan to treat patients with heart failure and reduced …

We performed a meta-analysis investigating the efficacy and adverse effects of sacubitril–
valsartan in various types of heart failure including more recent studies and a larger sample …

Background: Sacubitril/valsartan improves heart failure (HF) outcomes in patients with heart
failure with reduced ejection fraction (HFrEF). However, randomized controlled trials (RCTs) …

Background: PARADIGM-HF demonstrated superiority of sacubitril/valsartan (sac/val) over
enalapril in patients with heart failure with reduced ejection fraction (HFrEF). However …